IN184589B
(sl)
*
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
WO2001037804A2
(en)
*
|
1999-11-22 |
2001-05-31 |
Universal Preservation Technologies, Inc. |
Preservation and formulation of bioactive materials
|
JP5118798B2
(ja)
*
|
2000-03-07 |
2013-01-16 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アデノウイルス製剤
|
US7456009B2
(en)
*
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
US7153472B1
(en)
|
2000-11-22 |
2006-12-26 |
Quadrant Drug Delivery Limited |
Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
|
AU2002361545B2
(en)
*
|
2001-06-28 |
2007-03-15 |
Microchips, Inc. |
Methods for hermetically sealing microchip reservoir devices
|
AU2002353013A1
(en)
|
2001-12-03 |
2003-06-17 |
Massachusetts Institute Of Technology |
Microscale lyophilization and drying methods for the stabilization of molecules
|
KR101076335B1
(ko)
*
|
2002-03-13 |
2011-10-26 |
토마스 스쾰트 |
수성-기재 전달계
|
DE60336727D1
(de)
*
|
2002-08-16 |
2011-05-26 |
Microchips Inc |
Vorrichtung mit kontrollierter abgabe und verfahren
|
US7497855B2
(en)
*
|
2002-09-04 |
2009-03-03 |
Microchips, Inc. |
Method and device for the controlled delivery of parathyroid hormone
|
PL212483B1
(pl)
*
|
2002-09-27 |
2012-10-31 |
Powderject Res Ltd |
Sposób wytwarzania czasteczek, czasteczki odpowiednie do dostarczania, pojemnik, urzadzenie do dostarczania czasteczek i zastosowanie tych czasteczek
|
WO2004033034A1
(en)
|
2002-10-04 |
2004-04-22 |
Microchips, Inc. |
Medical device for neural stimulation and controlled drug delivery
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
EP2526996B1
(en)
|
2002-12-20 |
2019-09-11 |
Xeris Pharmaceuticals, Inc. |
Formulation for intracutaneous injection
|
US8084424B2
(en)
*
|
2003-04-09 |
2011-12-27 |
University Of Utah Research Foundation |
Compositions and methods related to erythropoietin
|
CA2523432C
(en)
*
|
2003-04-25 |
2014-10-28 |
Microchips, Inc. |
Solid drug formulation and device for storage and controlled delivery thereof
|
US7892205B2
(en)
|
2003-06-06 |
2011-02-22 |
Boston Scientific Scimed, Inc. |
Device and method for delivering micronized therapeutic agents in the body
|
CA2543751A1
(en)
*
|
2003-11-03 |
2005-05-12 |
Microchips, Inc. |
Medical device for sensing glucose
|
AU2005327211A1
(en)
*
|
2004-06-01 |
2006-08-17 |
Microchips, Inc. |
Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
|
WO2006015299A2
(en)
*
|
2004-07-30 |
2006-02-09 |
Microchips, Inc. |
Multi-reservoir device for transdermal drug delivery and sensing
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
ATE424928T1
(de)
*
|
2004-09-01 |
2009-03-15 |
Microchips Inc |
Behältervorrichtungen mit mehreren verschlüssen zur gesteuerten abgabe oder exponierung des behälterinhalts
|
CA2578817C
(en)
|
2004-09-10 |
2014-04-15 |
Becton, Dickinson And Company |
Reconstituting infusion device
|
AU2006208131A1
(en)
|
2005-01-25 |
2006-08-03 |
Microchips, Inc. |
Control of drug release by transient modification of local microenvironments
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
BRPI0620268B8
(pt)
*
|
2005-12-22 |
2021-05-25 |
Oakwood Laboratories LLC |
composição eficaz como sistema de fornecimento para liberação controlada, seu uso, seu método de fabricação, e método para proteger um agente biologicamente ativo
|
JP5143131B2
(ja)
|
2006-05-30 |
2013-02-13 |
インターシア セラピューティクス,インコーポレイティド |
浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
|
PL2359808T3
(pl)
|
2006-08-09 |
2013-10-31 |
Intarcia Therapeutics Inc |
Osmotyczne systemy dostawcze i zespoły tłokowe
|
AU2008234364B2
(en)
*
|
2007-03-30 |
2013-10-17 |
Altum-Avro Pharma Partnership |
Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery
|
CA2683610C
(en)
|
2007-04-23 |
2013-01-08 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
EP2170283B1
(en)
|
2007-06-22 |
2019-01-09 |
Board of Regents, The University of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
DK2240155T3
(da)
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
CA2743789C
(en)
|
2008-11-16 |
2017-10-31 |
Board Of Regents, The Univesity Of Texas System |
Low viscosity highly concentrated suspensions
|
ES2866623T3
(es)
*
|
2008-11-24 |
2021-10-19 |
Massachusetts Inst Technology |
Métodos y composiciones para el suministro localizado de nanopartículas a un tumor
|
KR101823699B1
(ko)
|
2009-09-28 |
2018-01-30 |
인타르시아 세라퓨틱스 인코포레이티드 |
실질 항정상태 약물 전달의 신속 확립 및/또는 종결
|
CA2792517C
(en)
*
|
2010-03-09 |
2020-03-24 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
US20110223208A1
(en)
*
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
CN102869345B
(zh)
|
2010-03-17 |
2015-02-11 |
诺瓦利克有限责任公司 |
用于治疗眼内压增高的药物组合物
|
US20120046225A1
(en)
|
2010-07-19 |
2012-02-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Stable glucagon formulations for the treatment of hypoglycemia
|
EP2444063A1
(en)
|
2010-10-20 |
2012-04-25 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the delivery of active ingredients
|
EP2462921A1
(en)
|
2010-11-11 |
2012-06-13 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the treatment of a posterior eye disease
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
AU2012225268B2
(en)
|
2011-03-10 |
2016-10-20 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of peptide drugs
|
PL2714010T3
(pl)
|
2011-05-25 |
2017-08-31 |
Novaliq Gmbh |
Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach
|
WO2012160180A2
(en)
|
2011-05-25 |
2012-11-29 |
Novaliq Gmbh |
Pharmaceutical composition for administration to nails
|
ES2574761T3
(es)
|
2011-10-31 |
2016-06-21 |
Xeris Pharmaceuticals, Inc. |
Formulaciones para el tratamiento de la diabetes
|
AU2013211645B2
(en)
|
2012-01-23 |
2017-06-15 |
Novaliq Gmbh |
Stabilised protein compositions based on semifluorinated alkanes
|
US9125805B2
(en)
|
2012-06-27 |
2015-09-08 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of small molecule drugs
|
EP3181119B1
(en)
|
2012-09-12 |
2019-07-10 |
Novaliq GmbH |
Semifluorinated alkane compositions for use in the treatment of keratoconjunctivitis sicca
|
EP2895158B1
(en)
|
2012-09-12 |
2019-11-20 |
Novaliq GmbH |
Compositions comprising mixtures of semifluorinated alkanes
|
JP6542128B2
(ja)
|
2013-01-11 |
2019-07-10 |
コルセア ファーマ インコーポレイテッド |
トレプロスチニルのプロドラッグ
|
US9505737B2
(en)
|
2013-01-11 |
2016-11-29 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
US9018162B2
(en)
|
2013-02-06 |
2015-04-28 |
Xeris Pharmaceuticals, Inc. |
Methods for rapidly treating severe hypoglycemia
|
TWI828269B
(zh)
*
|
2013-03-15 |
2024-01-01 |
美商百歐維拉提夫治療公司 |
因子ix多肽調配物
|
JP6503349B2
(ja)
|
2013-07-23 |
2019-04-17 |
ノバリック ゲーエムベーハー |
安定化された抗体組成物
|
US10159646B2
(en)
|
2013-08-12 |
2018-12-25 |
Altum-Avro Pharma Partnership |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
US8986732B2
(en)
|
2013-08-12 |
2015-03-24 |
Helix Biopharma Corporation |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
CN110559435B
(zh)
|
2013-09-11 |
2023-10-20 |
伊戈尔生物药品股份有限公司 |
包含离子性液体的液体蛋白质制剂
|
EP4043036A1
(en)
|
2013-09-27 |
2022-08-17 |
Massachusetts Institute of Technology |
Carrier-free biologically-active protein nanostructures
|
AU2015236340B2
(en)
*
|
2014-03-24 |
2020-02-06 |
Bioverativ Therapeutics Inc. |
Lyophilized factor IX formulations
|
EP3169660A1
(en)
|
2014-07-16 |
2017-05-24 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
AU2015300944B2
(en)
|
2014-08-06 |
2019-07-11 |
Xeris Pharmaceuticals, Inc. |
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
AU2015325055B2
(en)
|
2014-10-01 |
2021-02-25 |
Eagle Biologics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
MX2017015504A
(es)
|
2015-06-03 |
2018-05-15 |
Intarcia Therapeutics Inc |
Sistemas de colocacion y remoción de implante.
|
US9649364B2
(en)
|
2015-09-25 |
2017-05-16 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic formulations in aprotic polar solvents
|
US9643911B2
(en)
|
2015-06-17 |
2017-05-09 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
US9394227B1
(en)
|
2015-06-17 |
2016-07-19 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
US11034752B2
(en)
|
2015-08-12 |
2021-06-15 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
US11590205B2
(en)
|
2015-09-25 |
2023-02-28 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
|
DE202016008739U1
(de)
|
2015-09-30 |
2019-04-29 |
Novaliq Gmbh |
Semifluorierte Verbindungen
|
PT3355990T
(pt)
|
2015-09-30 |
2019-09-11 |
Novaliq Gmbh |
Compostos semifluorados e as suas composições
|
AU2017268161B2
(en)
|
2016-05-16 |
2020-03-12 |
Intarcia Therapeutics, Inc. |
Glucagon-receptor selective polypeptides and methods of use thereof
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
CN109715196A
(zh)
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
KR102257916B1
(ko)
|
2016-06-23 |
2021-05-28 |
노바리크 게엠베하 |
드롭 디스펜서를 포함하는 키트
|
CN109890374A
(zh)
|
2016-09-22 |
2019-06-14 |
诺瓦利克有限责任公司 |
用于治疗睑缘炎的药物组合物
|
JP6869336B2
(ja)
|
2016-09-23 |
2021-05-12 |
ノバリック ゲーエムベーハー |
シクロスポリンを含む眼科用組成物
|
AU2018206539A1
(en)
|
2017-01-03 |
2019-07-18 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
WO2018193093A1
(en)
|
2017-04-21 |
2018-10-25 |
Novaliq Gmbh |
Iodine compositions
|
CN110650734A
(zh)
|
2017-05-12 |
2020-01-03 |
诺瓦利克有限责任公司 |
治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
|
EP3624846A1
(en)
|
2017-05-16 |
2020-03-25 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
AU2018275686B2
(en)
|
2017-06-02 |
2024-02-01 |
Xeris Pharmaceuticals, Inc. |
Precipitation resistant small molecule drug formulations
|
AU2018328209A1
(en)
|
2017-09-05 |
2020-04-23 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
CN111372566A
(zh)
|
2017-09-27 |
2020-07-03 |
诺瓦利克有限责任公司 |
用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
|
US11896559B2
(en)
|
2017-10-04 |
2024-02-13 |
Novaliq Gmbh |
Opthalmic compositions comprising F6H8
|
WO2019166631A1
(en)
|
2018-03-02 |
2019-09-06 |
Novaliq Gmbh |
Pharmaceutical compositions comprising nebivolol
|
WO2019217637A1
(en)
*
|
2018-05-09 |
2019-11-14 |
Biomatrica, Inc. |
Stabilization of proteins in biological samples
|
CN112823020A
(zh)
|
2018-10-12 |
2021-05-18 |
诺瓦利克有限责任公司 |
用于治疗干眼病的眼用组合物
|
CN113661006A
(zh)
|
2019-02-05 |
2021-11-16 |
林迪生物科学公司 |
分离的细胞培养物组分以及用于从液体细胞培养基中分离其的方法
|
WO2021109979A1
(en)
|
2019-12-06 |
2021-06-10 |
Guangzhou Bioseal Biotech Co., Ltd. |
Flowable fibrinogen thrombin paste
|
US20230101362A1
(en)
*
|
2021-09-16 |
2023-03-30 |
Team Medical Llc |
Rna stabilization
|